Wang, Di The University of Tokushima
Iwata, Fusako Otsuka Pharmaceutical Co.
Muraguchi, Masahiro Otsuka Pharmaceutical Co.
Ooga, Keiko Otsuka Pharmaceutical Co.
Ohmoto, Yasukazu Otsuka Pharmaceutical Co.
Takai, Masaaki Otsuka Pharmaceutical Co.
Mori, Toyoki Otsuka Pharmaceutical Co.
salivary flow rate
Saliva samples are useful for noninvasive diagnosis of oral and systemic diseases. The water channel protein aquaporin-5 (AQP5) is released into human saliva. Salivary AQP5 levels show a diurnal variation with the secretion of high levels during the waking hours. An age-related decrease in salivary AQP5 levels parallels a decrease in the volume of saliva. Cevimeline, a muscarinic acetylcholine receptor (mAChR) agonist, induces the release of AQP5. Changes in salivary AQP5 levels after cevimeline administration occur simultaneously with changes in saliva flow rate. AQP5 and lipid rafts are released separately from human salivary glands upon M3 mAChR stimulation. In patients with diabetes mellitus or Sjögren’s syndrome, a decrease in salivary secretion occurs concomitantly with low salivary AQP5 levels. Salivary AQP5 levels correlate with salivary secretion in both healthy and disease states, suggesting that changes in salivary AQP5 levels can be used as an indicator of salivary flow rate and the effect of M3 mAChR agonists on human salivary glands.
The Journal of Medical Investigation
Faculty of Medicine Tokushima University
|DOI (Published Version)|
|URL ( Publisher's Version )|
jmi_56_suppl_350.pdf 458 KB